Hi Binkie,
Since I stopped taking Acyclovir I learned a couple things - first, you're supposed to start on a small dose and increase slowly. I started with 800 mg. So, there's that. Also, if you felt bad it might actually be a good sign that you are responding to treatment. It's not a herx reaction but something similar. It could last months before you feel better. So, I intend to start again soon on a low dose. I may do Valcyte or Valtrex instead of Acyclovir.
OH, I just remembered something important. Do you have a mycoplasma infection? (I take it you have herpes, epstein barr or some other chronic viral infection.) If you don't know, please get tested for it. I think it needs to be dealt with before starting anti-viral therapy. That's what the Physician's assistant at Stanford seems to think. Treating that is opening a whole new can of worms...
ALSO, and this is the most important thing, Binkie: any other viral "co-infection" needs to be treated first. According to Dr. Lerner, these must be addressed first before antiviral therapy is to be effective. Here is the abstract and a link to the full study. (You can skim through the Patients and methods section, but read the Purpose and Results and conclusions):
Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
Purpose: We hypothesized that chronic fatigue syndrome (CFS) may be caused by single or multiple Epstein–Barr virus (EBV), cytomegalovirus (HCMV), or human herpesvirus 6 (HHV6) infection. To determine if CFS life-altering fatigue and associated findings including muscle aches, tachycardia at rest, chest aches, left ventricular dysfunction, syncope, and elevated herpesvirus serum antibody titers are reversed by long-term subset-directed valacyclovir and/or valganciclovir.
Patients and methods: Data were collected at physician visits every 4–6 weeks from 142 CFS patients at one clinic from 2001 to 2007. To be included in this study, patients had to be followed for at least six months. The data captured included over 7000 patient visits and over 35,000 fields of information. Severity of fatigue was monitored by a validated Energy Index Point Score® (EIPS®). Baseline and follow-up serum antibody titers to EBV, HCMV, and HHV6, as well as coinfections with Borrelia burgdorferi, Anaplasma phagocytophila, Babesia microti, and antistreptolysin O, 24-hour ECG Holter monitors, 2D echocardiograms, cardiac dynamic studies, symptoms, and toxicity were captured and monitored. International criteria for CFS plus a specifically designed CFS diagnostic panel were used.
Results and conclusions: The Group A herpesvirus CFS patients (
no coinfections) returned to a near-normal to normal life (P = 0.0001). The long-term EIPS value increased (primary endpoint, P , 0.0001) with subset-directed long-term valacyclovir and/or valganciclovir therapy. Secondary endpoints (cardiac, immunologic, and neurocognitive abnormalities) improved or disappeared. Group B CFS patients (herpesvirus plus coinfections) continued to have CFS.
http://www.treatmentcenterforcfs.co...ment-of-142-herpesvirus-patients-with-CFS.pdf